About
|
Medical Team, Executive & Advisory Team
Dr. Felix Lurye - Medical Director
HarmoniXCell's Medical Director, Dr. Felix Lurye is a highly skilled and compassionate Board-Certified Anesthesiologist and Pain Medicine Specialist, serving as the Medical Director for Umbilical Cord Derived Stem Cell Use in our clinical team. With a foundation in patient-centered, evidence-based pain management, Dr. Lurye brings expertise on his regenerative medicine approach.
Dr. Lurye has administered hundreds of stem cell therapy protocols for his patients having tremendous success.
On his professional website, Dr. Lurye emphasizes, “Every patient is treated like family,” reflecting his commitment to delivering personalized, multimodal treatments aimed at restoring function and alleviating pain through the most effective, evidence-based approaches.
Education and Credentials
Mount Sinai Hospital Department of Anesthesiology, Perioperative, & Pain Medicine Icahn School of Medicine at Mount Sinai Pain Medicine Fellowship. Mount Sinai St. Lukes’s and Mount Sinai West Department of Anesthesiology, Perioperative, & Pain Medicine Icahn School of Medicine at Mount Sinai Anesthesiology Residency. St. George’s University School of Medicine Graduate Degree: Doctor of Medicine.
Dr Lurye specializes in managing a wide range of acute, subacute, and chronic disorders of the spine and musculoskeletal system—both degenerative and traumatic in nature. Dr. Lurye is well-versed in a comprehensive suite of advanced interventional pain treatments, including but not limited to:
Regenerative Umbilical Cord Derived Joint & Spine Injections
Laser discectomy and minimally invasive lumbar fusion
Epidural injections (cervical, thoracic, lumbar, caudal)
Facet joint injections, radiofrequency ablation, and rhizotomy
Nerve blocks (suprascapular, intercostal, occipital, ganglion impar)
Botox injections (for migraines and spasticity)
Platelet-rich plasma therapies
Spinal cord and dorsal root ganglion stimulation
Stacy Wright, RN- Medical Professional - Regenerative Aesthetics Specialist
HarmoniXCell's Aesthetics division and Regenerative Hair Restoration division called HAIRXCELL is run by Stacy Wright. Stacy’s proprietary Stem Cell and Exosome Hair Restoration Protocols (HAIRXCELL) have been successfully used on over 500 patients. Stacy can provide on-site training for your hair restoration patients, as well as cosmetic injection treatments using Stem Cell and Exosome protocols.
Stacy is a licensed, registered nurse with more than 20 years of experience in cosmetic and plastic surgery. As one of our valued nurse injectors and laser specialists at Stoker Plastic Surgery in Los Angeles, she is known for her gentle touch and exceptional technique, her ability to create natural results, and her keen insight into the needs of our patients.
Education and Credentials
Stacy earned a bachelor’s degree from Purdue University and completed her nursing degree at Los Angeles Harbor College. With two decades of experience in the cosmetic and plastic surgery field, Stacy creates custom treatment plans for each patient to help them achieve their goals and bolster their confidence. These customized plans may involve a variety of treatments, including:
Dermal fillers
BOTOX® Cosmetic
Ultherapy® skin tightening
IPL Photofacial
Laser Genesis
KYBELLA®
Chemical peels
Microneedling
CoolSculpting®.
Lisa Speer, Advanced Practice Registered Nurse (APRN)
Lisa is a highly respected Advanced Practiced Nurse that has conducted over 4,000+ stem cell procedures on patients in the United States. Lisa was co-author of recent Florida SB 1768 Stem cell Legislations Bill passed into Law July 1, 2025.
Anthony Rock - Advisory Board Member
Anthony (Tony) Rock retired from the U.S. Air Force in December of 2017 and is an independent consultant for Operations, Strategy, Leadership, and Defense topics. Tony served as President of Junior Achievement of South Texas leading staff and volunteers educating children on financial literacy, workforce readiness, and entrepreneurship preparing them to succeed in a global economy. During his 35-year military career Tony served as an operational F-15 instructor pilot and evaluator amassing over 4200 flying hours, and held a variety of command, staff, and senior leadership positions in the Air Force, Joint Services, and Interagency community. He commanded at multiple levels including a fighter squadron; a war-gaming, exercise and analysis center; and both fighter and expeditionary wings. Tony served in numerous locations around the world including Texas, Virginia, Florida, Idaho, Colorado, The Pentagon, Germany, Saudi Arabia, Iraq, and Pakistan and he is a combat veteran of Operations DESERT SHIELD/STORM, ENDURING FREEDOM, and IRAQI FREEDOM. Tony’s assignments as a senior officer included Deputy Director of Operations for U.S. Northern Command; Commandant of the U.S. Air Force Air Command and Staff College; Director of the Iraq Train and Advise Mission for Airpower; Vice Director of the Joint Staff’s Strategic Plans and Policy Directorate; Chief of the Office of U.S. Defense Representative-Pakistan; with his military career culminating as The Inspector General of the U.S. Air Force. Tony chaired the International Military Flight Training Conference 2018, 2022, and 2023, as well as the U.S. Military Flight Training Conference 2022 and 2023. He is currently Senior Advisor for Defense Affairs for NextEra Energy Resources of Juno Beach, Florida. Tony also serves as a member of the Air and Space Forces Association’s Strategic Industry Advisory Group, and is an advisor to GeneHarmonics, Inc.
Tony is a graduate of The University of Texas at San Antonio (B.A. History, 1982), and he earned master’s degrees from Embry-Riddle Aeronautical University (M.S. Aviation Science, 1995) and The U.S. Air Force Air War College (M.A. Strategic Studies, 2002). Tony, and his wife Kim, have 3 adult children: A.J and his wife Suzanne living in Austin, TX, Bennett and his wife Jessamyn assigned to Ft Rucker, Alabama, and Meggie and her partner Ben living in Austin, TX. Tony and Kim are also grandparents to 2 grandsons—Theodore and Winston.
Todd Hoisek - Executive Vice President
Todd Hoisek plays a pivotal role in the strategic growth and operational success of HarmoniXCell, the group’s regenerative therapy infrastructure division. In his capacity as Executive Vice President, Todd spearheads initiatives that expand access to advanced Umbilical Cord Blood (UCB) Stem Cell therapies for clinics and patients across the United States and Internationally.
Todd’s leadership focuses on building, educating, and empowering healthcare clinics to compliantly adopt regenerative therapies. He works closely with a diverse network of physicians, specialists, and healthcare organizations, guiding them through the latest science, protocols, and regulatory considerations in stem cell therapy. By coordinating peer-to-peer educational calls between HarmoniXCell’s medical team and clinical physicians, Todd ensures that each clinic receives not only the highest level of medical insight but also practical guidance for successful integration of stem cell therapies into their practice.
Todd’s broader career is defined by over 25 years of experience in business development, strategic partnerships, and operational leadership across multiple industries, with a particular emphasis on healthcare innovation. Committed to advancing the future of regenerative medicine, Todd brings not only an entrepreneurial vision but also a deep network of healthcare relationships that extend across wellness centers, orthopedic practices, pain management clinics, internal medicine groups, and specialty care providers. His work ensures that HarmoniXCell is not only a distributor of cutting-edge stem cell therapies but also a trusted partner in compliance, education, and patient-driven outcomes.
Through his leadership, Todd continues to shape HarmoniXCell into a premier regenerative therapy organization, combining scientific innovation, regulatory pathways, and clinical support into a comprehensive ecosystem designed to redefine patient care in the U.S. and globally.
Todd holds a B.A. in Business Sport Marketing from Mercyhurst University and is a committed mentor with Big Brothers Big Sisters.
Denny Roja - Vice President Legal Counsel
Denny S. Roja has over 30 years of experience in law, management, finance, and engineering. As a Silicon Valley venture lawyer, he served as managing partner of Venture Law Partners, a boutique law firm specializing in startups, and of counsel for Halloran Farkas & Kiwla, Carr McClellan and White & Lee where he handled various corporate transactions for emerging growth companies and tech startups, including venture capital financing, mergers & acquisitions, corporate formation, governance, contract negotiations, strategic partnerships, intellectual property licensing.
In the healthcare industry, he co-founded LiVeritas Biosciences. He served as Chairman of the Board of Professional Healthcare at Home and Nurse Providers, Inc., both of which were acquired by Mainsail Partners, a private equity fund. He has also been a venture capitalist at Boot-Up Ventures and Acuity Ventures, an early-stage Silicon Valley venture fund primarily investing in technology and internet software.
As an entrepreneur, Denny co-founded Daxa, a leader in AI-based cybersecurity software, and iSenseCloud, which develops innovative solutions in semiconductor metrology. As an investment banker, Denny was a managing director at VentureQuest International. This Silicon Valley-based investment banking firm provided corporate financial advisory and mergers and acquisitions services to technology firms.
He also previously directed mergers and acquisitions for two Fortune 50 companies—Kraft Heinz and General Foods, as well as AT&T (formerly Pacific Telesis). While serving as a Trustee of the Philippine Development Foundation, he spearheaded the development of a Silicon Valley-style infrastructure for entrepreneurship and innovation in the Philippines through a grant from the Department of Science and Technology.
He earned an MBA in Finance from Stanford University, a Juris Doctor degree from Fordham University Law School, and an MS in Chemical Engineering from the University of Washington, all on a National Science Foundation scholarship. Denny holds a B.S. in Chemical Engineering, summa cum laude, from the University of Santo Tomas.
David Keller - Chief Financial Officer
David Keller specializes in scaling operations of technology companies. His background combines finance, planning, sales operations, and business systems. His expertise includes business analysis, quality assurance, systems implementation, and technical support management. This encompasses the full range of P&L responsibilities, from leading distribution and audits for large subsidiaries of public companies to implementing systems for accounting, management information, security, and ERP.
In externally facing roles, David develops business programs for direct sales, channel partners, and networks of distributors and agents. His career has been international, spanning Asia, Europe, and the U.S. Building on earlier work in commercial banking and equities analysis, he transitioned from finance to operations by leading U.S. and Canadian operations for Fukuda Denshi, Japan’s largest independent public company specializing in medical equipment.
Most recently, David’s focus has been on scaling early-stage technology companies and launching new technology initiatives for large corporations. His recent work includes systems for Fast Retailing Co., Ltd. and The Kraft Heinz Company, as well as a security start-up, UbiVault LLC.
David also helped launch what is now HSBC’s investment banking arm in Tokyo by gaining a seat on the Tokyo Stock Exchange. He later directed research and strategy for France’s Crédit Lyonnais in Tokyo, one of the world’s ten largest banks at the time. In the U.S., he worked in business development in commercial banking in the Northwest for Mitsubishi Bank and Bank of California, including financing large-scale factories. David is fluent in Japanese.
Gil Masiglat - Vice President Asia-Pacific
Gil has over 30 years of experience in the pharmaceutical industry and has built strong professional relationships with leading industry giants across Asia. He developed his expertise in pharmaceutical manufacturing operations as the Managing Director of a pharmaceutical plant and played a pivotal role in saving lives during the COVID-19 pandemic.
His expertise extends to establishing and maintaining connections with major pharmaceutical API manufacturers, ensuring a seamless supply chain cycle, and driving strategic business development.
On behalf of HarmoniXCell, Gil is spearheading the company’s expansion into Asia, forging networks with leaders in aesthetics societies. He is also collaborating with the Department of Science and Technology and the Food and Drug Administration in the Philippines.
Additionally, Gil has built a strong franchise relationship with Zuellig Pharmaceutical Corporation (ZPC), where he contributed to pre-distribution planning across 13 Asia-Pacific countries, in which ZPC commands a dominant 70% market share.
Gil holds dual degrees in Business Administration (Management) and Customs and Tariff Administration.
IRB Clinical Trial Support
HarmoniXCell can recommend your clinic/practice/organization to enroll into an IRB Clinical Trial. These trials, conducted under Institutional Review Board (IRB) oversight, aim to determine the safety, tolerability, and efficacy of these stem cells, which are sourced from umbilical cord blood.
To enroll your clinic into IRB Clinical Trial and learn more, please visit www.scientificinfinity.com
Providing Highest Quality of Umbilical Cord Derived Stem Cells
Our Cord Blood lab partners focus on four essentials: quality, safety, flexibility, and cost—The outcome: a proven method that delivers maximum stem cell recovery and the highest level of transplant safety.
More Stem Cells, Every Time
No two cord blood collections are the same, so one of our lab partners created a process that consistently yields the largest possible number of stem cells in every situation.
The number of stem cells depends on factors like the mother’s age, prior pregnancies, and the volume collected. Since those elements are beyond control, the processing method itself becomes the deciding factor in stem cell recovery.
Our Lab Partners Vision
In any laboratory, minimizing contamination is critical. Our Lab Partners method uses a closed system, drastically reducing exposure to outside contaminants.
But safety extends further—into the transplant itself. Two key factors matter:
Red Cell Depletion – Red blood cells don’t survive freezing and thawing. They rupture, releasing hemoglobin and forming “ghost cells” that can cause illness in patients. The fewer red cells left, the safer the transplant. Our process removes Majority of red blood cells.
Cryo-preservative Quality – The right preservative must both protect stem cells during freezing and minimize toxicity for patients. Our formula achieves both, offering superior protection while being less toxic than alternatives used by other banks.
About Us
Follow us
General Questions & Sales Support
Email: [email protected]
Phone: 210-665-7340
Request Clinical Support
Email: [email protected]
Copyright© 2025 - All Rights Reserved.